Ikena Oncology Q2 2021 net loss $12.7M; cash $264M, IK-412 IND delayed by supply

ImageneBio, Inc.

Cash and cash equivalents $264.0M as of June 30, 2021; expected to fund operations through 2023.
Net loss $12.7M in Q2 2021 vs $5.0M in Q2 2020; R&D expense $11.4M vs $6.3M.
IK-930 IND submission on track for end of 2021; preclinical data at EORTC-NCI-AACR conference.
IK-175 monotherapy expansion cohort enrolling additional bladder cancer patients; clinical data planned in 2022.
IK-412 IND submission delayed due to shortage of a component required for COVID-19 vaccines.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.